<DOC>
	<DOCNO>NCT01208714</DOCNO>
	<brief_summary>Renal atherosclerotic stenosis ( RAS ) prevalent cause secondary hypertension ( HT ) . Since still uncertainties whether patient revascularization mean percutaneous renal angioplasty ( PTRAS ) pursue , design study exploit optimize patient selection strategy use hard experimental endpoint unravel uncertainty . Primary objective : determine revascularization mean PTRAS superior equivalent optimal medical treatment preserve glomerular filtration rate ischemic kidney assess 99mTcDTPA sequential renal scintiscan . Secondary objective : determine two treatment equivalent lower blood pressure ( BP ) , preserve overall renal function regress damage target organs hypertension . Design : prospective multicenter randomize , unblinded two-arm study . Eligible patient clinical and/or radiological evidence unilateral bilateral RAS , define stenosis proximal portion renal artery main bifurcation angioCT . Duplex scan exclude nephroangiosclerosis latter could bias assessment outcome revascularization . Inclusion criterion . RAS affect main renal artery major branch angio-CT either &gt; 70 % , &lt; 70 post-stenotic dilatation . Renal function assess 99mTc-DTPA renal scintigraphy . Sample size ( 30 patient per arm ) calculate 90 % power detect difference mean GFR vascularized ( control untreated kidney ) 7.5 ml/min . Arms 1 . Revascularization : digital scan angiography PTA stenting renal artery ostium truncular level , plus optimal medical therapy . 2 . Medical therapy : drug regimen optimize run-in period . Experimental endpoint : The absolute value GFR assess 99TcDTPA ischemic kidney use quantitative variable compare group time point . A categorical definition kidney loss , define GFR ischemic kidney &lt; 5 ml/min , also use rate achievement endpoint compare . Duration : 5 year .</brief_summary>
	<brief_title>Medical Endovascular Treatment Atherosclerotic Renal Artery Stenosis ( METRAS Study )</brief_title>
	<detailed_description>Background Renal atherosclerotic stenosis ( RAS ) increasingly prevalent cause secondary hypertension ( HT ) , become one first cause end-stage renal failure require renal replacement therapy age population . Atherosclerotic RAS associate high cardiovascular risk profile lead considerable excess rate morbidity mortality stroke , coronary heart peripheral vascular disease . Recent advance antihypertensive drug therapy intensive risk factor management prompt undertake prospective randomize trial compare percutaneous renal angioplasty ( PTRAS ) medical therapy . Unexpectedly , trial fail show compel benefit revascularization add effective medical therapy . However , serious limitation , raise number criticism , limited weight conclusion . Hence , clinician still leave uncertainty whether patient revascularization pursue . It conceivable study design exploit optimized patient selection strategy use hard experimental endpoint could resolve uncertainty thus lead well clinical management increase population atherosclerotic RAS . Objectives . The primary objective METRAS study determine revascularization mean PTRAS superior equivalent optimal medical treatment preserve glomerular filtration rate ischemic kidney assess 99TcDTPA sequential renal scintiscan . Secondary objective ( see appropriate section ) determine two treatment equivalent lower blood pressure ( BP ) , preserve overall renal function regress damage target organs hypertension . Design : prospective multicenter randomize , unblinded two-arm study . Enrolment . Eligible patient entail adult hypertensive gender clinical and/or radiological evidence unilateral bilateral RAS . Clinical evidence RAS unexplained renal dysfunction ( GFR &lt; 60 ml/min ) , uncontrolled refractory hypertension ( define resistant lifestyle measure least 3 drug include diuretic adequate dos failure lower systolic diastolic BP goal ) and/or significant worsen renal function ( 20 % increase serum creatinine ) administration ACE inhibitor and/or abdominal bruit and/or evidence atherosclerotic involvement site . Radiological evidence atherosclerotic RAS define stenosis proximal portion renal artery main bifurcation angioCT . Besides Angio-CT , patient undergo Duplex scan exclude nephroangiosclerosis latter could bias assessment outcome revascularization . Eligible subject offer participation METRAS study sign inform write consent . Inclusion criterion : angio-CT evidence RAS affect main renal artery major branch &gt; 70 % , &lt; 70 post-stenotic dilatation Exclusion criterion : see dedicated section . Run-in . Eligible patient undergo 4-week run-in period BP treatment , LDL-cholesterol , homocysteine glycemic control optimize . All patient receive antiplatelet treatment aspirin ticlopidine intolerant ASA , clopidogrel , intolerant ASA ticlopidine , throughout study period . AngioCT perform assess abdominal aorta renal artery anatomy pathology . RAS localization assess blindly 2 experienced radiologist . Precautions adopt minimize chance worsen renal function angioCT . 99mTc-DTPA renal scintigraphy perform 2 consecutive day , captopril administration , accord available guideline . Treatment ACEI/ARB stop 3-7 day ( depend drug half-life ) scintigraphy . If ACEI withdrawal hold unsafe , captopril scintigraphy omit baseline 99mTc-DTPA scintigraphy perform . All on-site measurement image validate core laboratory University Padova . Renal function assess MDRD formula reciprocal creatinine . Target organ damage ( TOD ) . Transthoracic echocardiogram Doppler assessment LV mass index , relative thickness , E/A wave peak flow velocity rate tissue Doppler use detect change LV remodel diastolic filling . Measurement pulse wave velocity , augmentation index use follow change aortic stiffness vascular damage . BP . Clinic ambulatory BP monitoring ( ABPM ) perform evaluate BP change treatment arm . ABPM use determine BP variability ( smoothness index ) day night . Randomization . A match algorithm consider RI presence unilateral/bilateral stenosis use randomly assign patient 2 treatment arm . This randomization strategy allow u obtain patient similar distribution RI equal number patient unilateral bilateral stenosis treatment arm . Sample size . Power calculation ( nQuery Vers , 6.0 , Statistical Solutions ) show assume 16 % drop-out rate , common standard deviation 8.0 ml/min , equal sample size treatment arm , use two group t-test 0.05 2-sided significance level , 30 patient per arm study 90 % power detect difference mean GFR vascularized ( control untreated kidney ) 7.5 ml/min . Treatment arm 1 . Revascularization . The patient randomize treatment undergo digital scan angiography ( DSA ) PTA stenting renal artery . PTA perform ostium truncular level . Stenoses involve distal arterial vessel record consider data analysis treat . The patient randomize revascularization continue antihypertensive drug regimen . The dose number drug down-titrated aim pursue target BP value . 2 . Medical therapy The patient randomize medical treatment continue antihypertensive drug regimen optimize reach BP goal run-in period . Experimental endpoint . The absolute value GFR assess 99TcDTPA ischemic kidney use quantitative variable compare group time point . Moreover , purpose Cox regression analysis categorical definition kidney loss , define GFR ischemic kidney &lt; 5 ml/min , use rate achievement endpoint compare . Potential confounders . To minimize untoward effect difference CV risk anti-platelet , lipid-lowering , antidiabetic agent , need , give patient , maintain dosage achieve end run-in period throughout study . The possible unbalanced distribution confounders treatment arm handle calculate propensity score ( 8 , 9 ) enter Cox regression analysis . Follow-up . Visits schedule 1 , 3 , 6 , 12 24 month revascularization begin medical therapy . The study continue observational setting outpatient visit schedule 6-month interval 5 year . Data collection . Data collect use specifically design database form ( create Open Clinica ; http : //www.openclinica.org ) ; monitor real time analyze core laboratory . Statistical analysis . Comparison GFR ischemic kidney group ( revascularization vs. medical therapy ) time point perform use t-test , repeat measure ANOVA adjustment potential confounders , Cox regression model loss kidney function define . Sub-group analysis ( comparison unilateral v bilateral stenosis ) similarly undertaken . ROC curve use determine baseline 99mTc DTPA scintiscan-derived index predict outcome treatment use change GFR time reference . Bland-Altman plot analysis use compare estimate GFR obtain use cystatin use overall ( right leave kidney ) GFR reference . Multivariate technique propensity score , considers relevant covariables differ revascularization medical treatment rate group , use avoid untoward effect possible unbalanced distribution confounders treatment arm ( D'Agostino RB , Jr . Circulation 2007 ; Maiolino G. JCEM 2008 ) . Expected result . The Metras study clarify whether renal revascularization mean PTRAS associate optimal medical therapy superior equivalent optimal medical treatment alone prevent deterioration renal function , assess GFR ischemic kidney . A previous study Radermacher et al suggest presence irreversible renal microvascular change , e.g . nephroangiosclerosis , could prevent patient benefit revascularization . In fact intrarenal resistance index ( RI ) &gt; 0.80 Doppler analysis claim predict improvement BP renal function , assess measure creatinine clearance . However , latter index global function , therefore provide information GFR ischemic kidney . This study , randomize patient match RI value , expect clarify whether endovascular treatment slow GFR loss even patient nephroangiosclerosis . Moreover , meet secondary endpoint help clarify clinically relevant issue BP lowering , rate renal major cardiovascular event , change quality life with/without endovascular treatment patient atherosclerotic RAS . Duration study . The METRAS Study last 5 year . This time interval expect sufficient register renal major cardiovascular event . Centers . This study perform within Italian Society Arterial Hypertension ( SIIA ) achieve randomization number patient need provide significant power study . A core laboratory Padova adjudicate eligible patient randomize patient . Conclusions Perspectives . The METRAS Study design provide conclusive answer debate question : angioplasty combine stenting associate optimal medical therapy equivalent optimal medical treatment alone prevent deterioration renal function , assess GFR ischemic kidney ? A novel approach , consist evaluate deterioration renal function , assess GFR ischemic kidney , rather overall GFR , clarify PTRAS protect kidney stenotic artery functional decline .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<criteria>RAS affect main renal artery major branch angioCT either &gt; 70 % , &lt; 70 poststenotic dilatation AND resistance index ( RI ) &lt; 0.55 &gt; 0.55 &lt; 0.80 evidence intrarenal heterogeneity RI reveal CV &gt; 10 % RI across upper , mid low third kidney . refusal participate study , previous endovascular surgical treatment RAS , fibromuscular RAS , plan actual pregnancy , childbearing potential without measure adequate prevent pregnancy , life expectancy &lt; 2 year , patient currently participate another trial possibly influence safety patient and/or outcome study , comorbid condition limit participation followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Renal artery stenosis</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Arterial hypertension</keyword>
	<keyword>Percutaneous renal angioplasty</keyword>
	<keyword>Stenting</keyword>
</DOC>